Galapagos beefs up its fibrosis pipeline, lassoing 4 more programs and taking a stake in small Canadian partner
With big money pacts with Gilead and AbbVie under its belt, Galapagos has become a hefty partner to smaller biotech players in its own right.
The Belgian biotech has expanded a collaboration with Fibrocor Therapeutics — grabbing exclusive options to four more fibrosis programs and taking an equity stake in the company. Once Fibrocor completes the research work up to lead optimization, Galapagos may take over development.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,500+ biopharma pros reading Endpoints daily — and it's free.